Surfactant in Pregnancy and Fetal Lung Development

Pulmonary surfactant is the thin film of fats and proteins that coats the inside of the lungs and keeps air sacs from collapsing every time you exhale. A fetus does not produce meaningful amounts of it until the third trimester, and the gap between when a baby might be born early and when its lungs are ready to work on their own is one of the central dramas of perinatal medicine. Understanding how surfactant forms, what speeds it up, and what slows it down shapes virtually every clinical decision around preterm birth.

What Surfactant Actually Is

Surfactant is a mixture of lipids and a handful of specialized proteins, produced by cells lining the deepest pockets of the lung. The lipid portion makes up roughly 90 percent by weight, with phosphatidylcholine dominating the mix. One species of that lipid, called DPPC, accounts for somewhere between 40 and 70 percent of all the phosphatidylcholine present and is the chief ingredient responsible for lowering surface tension.¹ A second phospholipid, phosphatidylglycerol, shows up in smaller quantities but has recently drawn attention for a role in immune defense.²

The protein fraction is small, around 10 percent by weight, but essential. Four surfactant proteins have been identified. SP-A and SP-D are relatively large, water-soluble molecules that belong to the collectin family, a group of immune-recognition proteins. SP-B and SP-C are tiny, extremely fat-loving molecules that sit within the lipid layers and help surfactant spread across the air-liquid interface.¹ Without SP-B and SP-C, the lipids alone cannot form a functional film; without SP-A and SP-D, the lungs lose a first line of defense against infection.

How Surfactant Works at the Air-Liquid Interface

Every alveolus, the tiny air sac where gas exchange happens, is lined with a razor-thin layer of water. Water molecules pull on each other, creating surface tension that would collapse an empty alveolus if left unchecked. Surfactant sits at this water-air boundary and dramatically lowers that pull. When you exhale and the alveolus shrinks, surfactant molecules are compressed together, reducing surface tension to remarkably low levels and preventing the sac from snapping shut.³

The mechanism is elegant. As the alveolar surface area decreases during exhalation, surfactant constituents pack tightly at the interface, reaching concentrations high enough to push surface tension well below the equilibrium value that the same mixture would produce in a test tube.⁴ Non-DPPC components are gradually squeezed out of the surface layer, leaving behind a nearly pure DPPC film that behaves almost like a solid sheet.⁵ This is why DPPC content matters so much: it is the ingredient that, under compression, resists collapse and holds the alveolus open.

When the Fetal Lung Starts Making Surfactant

Fetal lungs go through several overlapping stages of development, and surfactant production does not begin in earnest until the canalicular and saccular stages of the third trimester. In studies tracking human fetal tissue, the type II alveolar cells responsible for making surfactant are essentially undetectable before about 22 to 25 weeks of gestation. They start to appear around 26 weeks, become noticeably more abundant after 28 weeks, and by 34 weeks surfactant has spread throughout the alveolar spaces.⁶

Before type II cells can release surfactant, they first have to package it. Surfactant lipids and proteins are stored inside specialized organelles called lamellar bodies, tightly packed stacks of concentric membrane layers that function as storage-and-delivery units.⁷ When the cell is ready, these lamellar bodies fuse with the cell membrane and release their contents into the thin fluid layer lining the alveolus. The practical takeaway: a baby born before type II cells are producing and exporting enough lamellar bodies will have lungs that cannot stay inflated on their own.

Hormonal Drivers of Lung Maturation

The fetal adrenal glands ramp up cortisol output during the final weeks of pregnancy, and this hormonal surge is one of the most important triggers of surfactant production. Animal studies have shown that giving cortisol directly to a fetus roughly doubles the amount of phospholipid recoverable from the lungs and shifts the lipid composition toward a profile normally seen at a later gestational age.⁸ In other words, corticosteroids accelerate the clock, pushing the lung to behave as though it is older than it actually is.

This cortisol-driven pathway also explains why certain maternal conditions can derail surfactant readiness. Maternal diabetes, whether pre-existing or gestational, can delay surfactant maturation. The combination of high blood sugar and the resulting spike in fetal insulin appears to interfere with both the lipid and protein arms of surfactant synthesis.⁹ Experimental work in sheep has shown that infusing glucose into the fetus reduces surfactant protein gene expression in the lung, with evidence pointing to disrupted glucocorticoid signaling as the mechanism.¹⁰ The clinical consequence is well documented: the appearance of phosphatidylglycerol in amniotic fluid, a classic marker of lung readiness, is delayed in pregnancies complicated by poorly controlled diabetes.¹¹

What Happens When Surfactant Is Missing

The disease that results from inadequate surfactant in a newborn is called respiratory distress syndrome, historically known as hyaline membrane disease. In a preterm baby the cause is straightforward: the lungs are too immature to make enough surfactant. In a term baby the situation can be more complex. Some full-term infants develop surfactant deficiency because of exposure to conditions that delayed synthesis, such as maternal diabetes, or because of a genetic mutation that produces dysfunctional surfactant.¹²

Without surfactant, the high surface tension in the alveoli causes them to collapse with every breath, a condition called atelectasis. The resulting poor gas exchange drives severe oxygen deprivation and acid buildup. The damaged alveolar lining becomes abnormally leaky, allowing fluid and proteins to seep into the air spaces.¹³ That fluid mixes with dead cells and fibrin to form the hallmark “hyaline membranes,” glassy sheets visible under a microscope that gave the disease its original name.¹⁴

Antenatal Corticosteroids to Speed Things Up

Because the fetal cortisol surge is so critical to surfactant production, clinicians have long exploited that biology by giving corticosteroids to pregnant women at risk of delivering early. A Cochrane review of the available trials supports the continued use of a single course of antenatal corticosteroids to accelerate fetal lung maturation.¹⁵ The benefit extends even into the late preterm window: a large trial found that giving betamethasone to women at risk of delivering between 34 and 36 weeks reduced the rate of severe respiratory complications, surfactant use, and related lung problems in newborns.¹⁶

When delivery does not happen within the expected window and a week or more passes after the first course, repeat doses become a consideration. Repeat courses reduce the risk of respiratory distress syndrome by about 17 percent and the risk of serious neonatal illness by about 16 percent compared with a single course.¹⁷ The trade-off is a small reduction in birth weight, and the size of that reduction is related to how many repeat courses are given. An individual-participant meta-analysis concluded that it is prudent to cap repeat treatment at a maximum of three additional courses.¹⁸ Follow-up of children who received repeat prenatal steroids has not shown significant differences in developmental testing or body size at around two and a half years, though one trial observed a numerically higher but statistically non-significant rate of cerebral palsy in the repeat-steroid group.¹⁹

Surfactant Replacement After Birth

The first clinical trial of surfactant replacement therapy for newborns with respiratory distress syndrome took place in 1980, and survival rates for extremely premature infants improved dramatically in the years that followed.²⁰ Two broad categories of replacement surfactant exist. Natural surfactant extracts, derived from animal lungs, contain the hydrophobic proteins SP-B and SP-C along with the lipids. Early synthetic formulations were protein-free. A Cochrane meta-analysis found that natural extracts reduced the risk of air leak in the lung by about a third and lowered mortality compared with protein-free synthetics.²¹ Smaller comparative studies have since suggested that the gap may be narrower than originally thought, with one retrospective analysis finding similar ventilator needs, hospital stays, and mortality between a bovine-derived preparation and a protein-free synthetic, along with a meaningful cost difference favoring the synthetic.²² Newer-generation synthetic surfactants now incorporate peptide analogues of SP-B, aiming to combine the performance of animal-derived products with the consistency and lower cost of synthetics.

How surfactant is delivered matters too. The traditional method involves intubating the baby, instilling the surfactant through the breathing tube, and then either continuing mechanical ventilation or quickly removing the tube. A less invasive approach, known as LISA, threads a thin catheter past the vocal cords while the baby continues to breathe on its own, avoiding the need for positive-pressure ventilation altogether. Randomized trials and meta-analyses indicate that LISA reduces the chance of needing mechanical ventilation and is associated with lower rates of chronic lung disease and brain hemorrhage.^{23 24}

Looking further ahead, researchers are exploring aerosolized surfactant, delivered through a mask or nasal prongs rather than through any tube at all. Current technology for aerosolization has improved enough to raise the possibility that nebulized surfactant could be administered in a wider range of settings, including hospitals without a full neonatal intensive care unit.²⁵ If that pans out, it could change the geography of neonatal care in resource-limited areas, where intubation-dependent surfactant delivery is often unavailable.

Genetic Conditions That Disrupt Surfactant

Some babies are born at term with lungs that look mature but still cannot produce functional surfactant, because a gene essential to the process is mutated. The best-characterized genetic surfactant disorders involve three genes. Mutations in the SP-B gene tend to cause fatal respiratory failure in the first days of life. Mutations in the SP-C gene more commonly cause a slower-burning interstitial lung disease that can present in older infants, children, or even adults. Mutations in the ABCA3 gene, which encodes a lipid transporter involved in building lamellar bodies, can produce either pattern.²⁶

ABCA3 mutations turned out to be surprisingly common among newborns who died of unexplained surfactant deficiency. In one study of 21 such infants, 76 percent carried identifiable ABCA3 mutations.²⁷ These conditions are inherited in an autosomal recessive pattern for SP-B and ABCA3 and often in a dominant pattern for SP-C. Genetic testing is now part of the workup for any term infant with unexplained, persistent respiratory failure, and it has reshaped the counseling these families receive. For the most severe SP-B deficiency, lung transplantation remains the only definitive treatment.

Surfactant’s Immune Role in the Fetal and Newborn Lung

Surfactant is not just a mechanical lubricant. The collectin proteins SP-A and SP-D act as pattern-recognition molecules, binding to the surfaces of bacteria, viruses, and fungi and flagging them for destruction by immune cells such as macrophages.²⁸ They also bind directly to the surfaces of those immune cells, either ramping up or dialing down their activity depending on the context.²⁹

Animal experiments have underscored how important this immune arm is. Mice genetically engineered to lack SP-A or SP-D become significantly more vulnerable to lung infections from organisms including Group B Streptococcus, Pseudomonas, and respiratory syncytial virus.³⁰ For a newborn transitioning from the sterile womb to a world teeming with microbes, having these immune molecules in place at birth adds a layer of protection during a uniquely vulnerable window. It also means that premature infants who lack surfactant are doubly disadvantaged: their alveoli collapse, and their innate lung defenses are weakened.

Smoking, Toxins, and Fetal Surfactant

Maternal smoking introduces another variable into fetal lung development. Nicotine crosses the placenta readily, and nicotinic receptors have been found on the same type II alveolar cells that produce surfactant. The co-localization of these receptors with surfactant-specific proteins suggests a plausible route by which nicotine could alter surfactant metabolism.³¹ Epidemiologically, maternal smoking is linked to postnatal changes in lung mechanics and higher rates of wheezing and coughing in exposed offspring.

In rat models, exposure to sidestream cigarette smoke around the time of birth reduced levels of SP-A on the first day of life, and by three weeks of age the exposed pups showed elevated SP-A and total phospholipid levels compared with controls, a rebound pattern suggesting the surfactant system was reacting to the insult. Interestingly, the surface-tension-lowering ability of the surfactant itself was not measurably impaired at any time point.³² That does not mean smoking is safe for fetal lungs; the compositional shifts and the downstream airway changes linked to nicotine exposure are real. But it does highlight that surfactant function is resilient, and not every biochemical perturbation translates directly into impaired surface tension.

Long-Term Lung Health After Surfactant Therapy

Surfactant replacement has been a game-changer for neonatal survival, but what about the lungs years later? One early study measured lung function in late infancy and found that babies who had received surfactant for respiratory distress syndrome showed lower airway resistance and better airflow on forced expiration compared with placebo-treated controls.³³ That suggests surfactant therapy may carry long-term benefits for how well the airways function, at least in larger preterm infants.

The picture is more complicated for the tiniest babies. Mortality among infants born weighing under one kilogram has dropped substantially thanks to the combination of surfactant, antenatal steroids, and gentler ventilation strategies, but many survivors develop a chronic lung disease characterized by arrested development of the alveoli themselves.³⁴ Called bronchopulmonary dysplasia, this condition reflects not just a surfactant problem but a deeper disruption of alveolar growth triggered by prematurity, oxygen exposure, and mechanical ventilation. Surfactant alone cannot undo that developmental insult. It keeps the baby alive through the critical first days, but the subsequent weeks of intensive care carry their own risks to lung architecture.

An Ancient Molecule

Pulmonary surfactant is not a recent evolutionary invention. Comparative research has found SP-A-like proteins and corresponding messenger RNA in every major vertebrate group examined, from fish to amphibians to reptiles to mammals. The implication is that the surfactant system arose once, before the vertebrate lineage diversified, and has been conserved ever since.³⁵ SP-A has even been identified in the swim bladder of goldfish, an organ that evolved from an ancestral air-breathing structure but no longer serves that function. Over time the lipid composition of surfactant has shifted in response to body temperature and other selection pressures, but the core system has remained remarkably stable.³⁶ The evolution of surfactant was likely a prerequisite for air breathing itself. Without a way to keep wet surfaces from sticking together, any gas-exchange organ built around delicate, thin-walled sacs would simply collapse.